Visit Aggrego Advances hub to learn more about the late breaking developments from the POSEIDON trial 

Friday
March
24
Top Stories
The Impact of Lymphovascular Space Invasion on Survival in Early Stage Low-Grade Endometrioid Endometrial Cancer

The present study was aimed to evaluate the impact of LVSI on survival in patients with early stage endometrioid endometrial cancer.

European Journal of Medical Research
1h ago
Aggrego Pulse - 3/23/23

On this week's episode of Aggrego Pulse, Dr Brian Van Tine, a professor of Sarcoma Oncology at Washington University in St.

Aggrego Oncology
2d ago
Can Lymph Nodes Boost the Success of Cancer Immunotherapy?

New study findings from a clinical trial by researchers at UC San Francisco and Gladstone Institutes demonstrates that immunotherapy can activate tumor-fighting T cells in nearby lymph nodes.

UCSF
2d ago
Response High for Bispecific Antibody Talquetamab in Multiple Myeloma

A substantial proportion of patients with heavily pretreated multiple myeloma responded to treatment with the bispecific antibody talquetamab, according to results of a phase I study published in

ASH Clinical News
2d ago

Spotlight

Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy.